BUZZ-Australia's Neurotech International jumps as US FDA grants rare disease status for drug candidate

Reuters
2025/10/08
BUZZ-Australia's <a href="https://laohu8.com/S/NTI.AU">Neurotech International</a> jumps as US FDA grants rare disease status for drug candidate

** Shares of Australia's Neurotech International NTI.AX rise as much as 52.6% to A$0.029, their biggest intraday pct gain since early-July 2020

** Stock at its highest level since April 23

** NTI stock up 10.5% currently

** Biopharmaceutical co says U.S. FDA granted rare pediatric disease designation for drug candidate, NTI164, for treatment of Rett syndrome

** Rett syndrome is a rare genetic neurological and developmental disorder that affects ways in which brain develops

** Nearly 15.3 million shares change hands, 13.2x the 30-day average volume

** Stock has fallen 61.8% this year, as 0024 GMT

(Reporting by Roshan Thomas in Bengaluru)

((Roshan.Thomas@thomsonreuters.com))

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10